CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Rare Genetic Variants Associated With Sudden Cardiac Death in Adults Spontaneous Coronary Artery Dissection: JACC State-of-the-Art Review Microthrombi As A Major Cause of Cardiac Injury in COVID-19: A Pathologic Study Contrast-Associated Acute Kidney Injury and Serious Adverse Outcomes Following Angiography Select Drug-Drug Interactions With Direct Oral Anticoagulants Dynamic atrioventricular delay programming improves ventricular electrical synchronization as evaluated by 3D vectorcardiography Coronary Plaque Features on CTA Can Identify Patients at Increased Risk of Cardiovascular Events Poor R-wave progression as a predictor of sudden cardiac death in general population and subjects with coronary artery disease

Review ArticleVolume 75, Issue 11, March 2020

JOURNAL:J Am Coll Cardiol. Article Link

Select Drug-Drug Interactions With Direct Oral Anticoagulants

BS Wiggins, DL Dixon, RR Neyens et al. Keywords: DOACs; drug-drug interactions; P-glycoprotein

ABSTRACT


Millions of individuals in the United States require long-term treatment with an oral anticoagulant. For decades, vitamin K antagonists were the only oral option available; however, they have a number of well-known limitations. Introduction of the direct oral anticoagulants (DOACs) has long been considered a major therapeutic advance, largely because they lack the need for therapeutic monitoring. Despite this, DOACs, like vitamin K antagonists, can still cause major and clinically relevant nonmajor bleeding, even when used appropriately. Drug-drug interactions (DDIs) involving the DOACs represent an important contributor to increased bleeding risk. Awareness of these DDIs and how best to address them is of critical importance in optimizing management while mitigating bleeding risk. This review provides an overview of DOAC metabolism, the most common drugs likely to contribute to DOAC DDIs, their underlying mechanisms, and how best to address them.